The__O DOSE__B-MISC index__O Treatment__O decisions__O for__O COPD__O depend__O crucially__O on__O an__O accurate__O prediction__O of__O the__O future__O progression__O of__O the__O disease,__O and__O treatment__O guidelines__O recommend__O physicians__O to__O assess__O disease__O severity.__O
Of__O the__O several__O multi-system__O indicators__O available,__O both__O the__O DOSE__B-ORG and__O the__O BODE__B-ORG are__O significant__O predictors__O of__O mortality__O [2]__O but__O the__O DOSE__B-MISC index__O is__O simpler__O and__O cheaper__O to__O use__O compared__O with__O the__O BODE__B-ORG index.__O
The__O BODE__B-MISC index__O is__O the__O most__O commonly__O cited__O index__O of__O severity__O in__O research__O studies,__O but__O is__O virtually__O never__O used__O in__O primary__O and__O secondary__O care.__O
A__O 2012__O analysis__O of__O 14610__O records__O on__O the__O OPC__B-ORG database__O of__O patients__O with__O a__O diagnosis__O of__O COPD__B-ORG revealed__O no__O case__O for__O which__O there__O was__O a__O complete__O BODE__B-ORG score__O [3].__O
This__O is__O because__O the__O BODE__B-ORG requires__O trained__O staff__O to__O conduct__O a__O six__O minute__O walk__O test__O along__O a__O 30__O metre__O corridor,__O with__O total__O administration__O time__O of__O at__O least__O twice__O that__O time__O (&gt;12__O minutes).__O
In__O contrast__O the__O DOSE__B-MISC index__O consists__O of__O 4__O items__O which__O according__O to__O NICE__B-ORG recommendation__O should__O be__O part__O of__O the__O routine__O assessment__O of__O patients__O in__O all__O settings__O (NICE__O CG__O 101),__O and__O so__O for__O many__O patients__O incurs__O no__O additional__O costs__O for__O assessment.__O
The__O same__O 2012__O analysis__O of__O the__O 2012__O OPC__B-ORG database__O revealed__O that__O around__O half__O of__O COPD__B-ORG patients__O (7,228__O of__O 14,610)__O had__O a__O valid__O DOSE__B-MISC index__O properly__O recorded.__O
If__O the__O indicators__O for__O the__O DOSE__B-ORG are__O not__O collected__O (i.e.,__O about__O 50%__O of__O this__O sample)__O then__O guidelines__O are__O not__O being__O followed.__O
The__O DOSE__B-MISC index__O and__O associated__O management__O recommendations__O can__O be__O automatically__O computed__O from__O routinely__O collected__O data__O by__O data__O analysis__O systems__O such__O as__O the__O OPC__B-ORG COPD__B-MISC reporting__O service__O (http://www.optimumpatientcare.org/),__O and__O the__O Health__B-ORG Intelligence__I-ORG risk__O stratification__O service__O (http://www.health-intelligence.com/population-based-risk-stratification.html).__O
This__O means__O that__O the__O NHS__B-ORG staff__O require__O no__O extra__O work__O to__O obtain__O the__O DOSE__B-ORG score__O other__O than__O that__O required__O by__O following__O the__O NICE__B-ORG guidelines.__O
By__O calculating__O a__O DOSE__B-ORG score__O they__O are__O thereby__O able__O to__O identify__O patients__O in__O need__O of__O intensive__O management.__O
The__O DOSE__B-MISC index__O has__O been__O widely__O adopted__O internationally__O and__O has__O led__O to__O changes__O in__O recommended__O guidance__O worldwide__O in__O terms__O of__O assessing__O disease__O severity.__O
The__O following__O guidelines__O or__O organisations__O recommend__O the__O use__O of__O the__O DOSE:__B-MISC (a)__I-MISC The__I-MISC Global__I-MISC initiative__O for__O Chronic__O Obstructive__O Lung__O Disease__B-MISC (GOLD)__B-ORG 2011__O guidelines,__O which__O are__O the__O most__O influential__O in__O the__O world,__O recommend__O the__O DOSE__B-ORG for__O assessing__O disease__O severity__O [1].__O
(b)__O `Diagnosis__O and__O management__O of__O COPD__B-ORG in__O primary__O care:__O A__O guide__O for__O those__O working__O in__O primary__O care'__O (Primary__B-ORG Care__I-ORG Respiratory__I-ORG Society,__I-ORG Third__I-ORG Edition,__I-ORG 2010)__O [4]__O (c)__O IMPRESS__O guidelines__O (an__O organisation__O that__O links__O the__O British__B-ORG Thoracic__I-ORG Society__I-ORG with__O the__O Primary__B-MISC Care__I-MISC respiratory__O society)__O [5]__O and__O (d)__O the__O COPD__B-ORG exchange__O educational__O website__O with__O &gt;7,500__O registered__O members__O in__O 2012__O recommends__O the__O DOSE__B-MISC index__O in__O routine__O clinical__O care__O [6].__O
A__O UK__B-LOC company__O used__O by__O NHS__B-ORG commissioners__O (Health__B-PER Intelligence)__I-PER uses__O the__O DOSE__B-MISC index__O to__O stratify__O risk__O for__O people__O with__O COPD,__B-MISC and__O thereby__O determine__O treatment__O selection.__O
The__O DOSE__B-MISC index__O is__O also__O used__O by__O a__O patient__O management__O organisation,__O Optimal__B-ORG Patient__I-ORG Care,__I-ORG which__O has__O been__O providing__O assessments__O using__O the__O DOSE__B-MISC index__O on__O 7000__O patients__O annually__O over__O the__O last__O three__O years__O [3].__O
The__O results__O are__O returned__O to__O doctors__O and__O patients,__O and__O the__O scores__O are__O used__O to__O assess__O disease__O severity__O and__O guide__O treatment__O recommendations.__O
The__O National__B-ORG COPD__I-ORG audit__O is__O a__O Department__B-ORG of__I-ORG Health__I-ORG initiative__O similar__O to__O the__O diabetes__O and__O cancer__O audits.__O
The__O audit__O is__O currently__O being__O developed__O with__O first__O data__O collection__O due__O in__O late__O 2013.__O
It__O aims__O to__O include__O nearly__O all__O 800,000__O patients__O in__O primary__O care__O with__O a__O registered__O diagnosis__O of__O COPD.__B-LOC
One__O of__O the__O key__O items__O being__O used__O to__O assess__O disease__O severity__O and__O progression__O is__O the__O DOSE__B-MISC index__O [7].__O
The__O DOSE__B-MISC index__O is__O used__O as__O part__O of__O a__O COPD__B-ORG management__O template__O which__O has__O been__O developed__O by__O the__O Primary__B-ORG Care__I-ORG Respiratory__I-ORG Society__I-ORG in__O conjunction__O with__O Almirall__O (a__O pharmaceutical__O company)__O and__O the__O Department__B-ORG of__I-ORG Health.__I-ORG
The__O template__O is__O currently__O in__O beta-testing__O with__O 1,000__O practices__O per__O year__O scheduled__O to__O receive__O it__O over__O the__O next__O 3__O years__O [7].__O
The__O template__O is__O being__O used__O in__O primary__O care__O to__O assess__O disease__O severity__O and__O to__O estimate__O future__O risk__O of__O progression__O and__O complications.__O
The__O template__O provides__O management__O decision__O support__O based__O on__O the__O DOSE__B-MISC index__O and__O other__O data.__O
The__O LINQ__B-ORG The__I-ORG LINQ__I-ORG has__O achieved__O the__O following__O changes__O to__O clinical__O practice:__O It__O provides__O a__O convenient__O way__O of__O helping__O clinicians__O identify__O patients'__O information__O needs__O prior__O to__O the__O clinical__O interview__O so__O that__O the__O clinician__O can__O focus__O on__O the__O topics__O where__O the__O patient__O has__O information__O needs.__O
Our__O research__O shows__O that__O its__O use__O improves__O patient__O education__O as__O well__O as__O anxiety.__O
When__O used__O in__O an__O integrated__O education__O package,__O it__O has__O been__O shown__O to__O significantly__O reduce__O rate__O of__O hospitalisation,__O with__O patients__O being__O less__O breathless__O and__O having__O improved__O daily__O living__O activities__O (Wakabayashi__B-MISC et__O al.,__O 2011).__O
Its__O use__O has__O also__O been__O extended__O to__O other__O respiratory__O diseases__O [8].__B-ORG
The__O LINQ__O is__O currently__O used__O in__O specialist__O respiratory__O units,__O pulmonary__O rehabilitation__O programmes__O and__O in__O primary__O care__O both__O in__O the__O UK__B-LOC and__O worldwide.__O
Its__O use__O is__O recommended__O in__O various__O guidelines,__O including__O Impress__B-ORG [5]__I-ORG and__O the__O COPD__B-ORG Exchange__I-ORG [6]__O which__O has__O approximately__O 500__O registered__O users.__O
The__O scale__O has__O been__O translated__O into__O 11__O languages__O [9].__O
In__O Japan,__B-ORG the__I-ORG LINQ__I-ORG is__O currently__O used__O in__O 26__O institutions__O where__O it__O is__O used__O in__O patient__O care__O by__O 9__O physicians,__O 7__O nurses,__O 4__O physiotherapists,__O 1__O pharmacist,__O 5__O university__O nursing__O departments__O [10],__B-ORG and__O a__O LINQ__B-ORG book__O has__O been__O written__O on__O the__O information__O that__O should__O be__O provided__O to__O patients__O [11].__B-MISC
In__O Canada__B-LOC its__O use__O is__O reflected__O in__O the__O development__O of__O a__O scoring__O template__O by__O a__O Canadian__B-MISC physician__O that__O is__O now__O available__O on__O the__O LINQ__B-ORG website,__O hosted__O by__O Plymouth__B-ORG University__I-ORG [8].__I-ORG
Its__O use__O across__O different__O countries__O is__O reflected__O in__O the__O number__O of__O hits__O on__O the__O website:__O 200,000__O between__O December__O 2011__O and__O January__O 2013,__O and__O the__O number__O of__O downloads__O of__O translations__O of__O the__O questionnaire__O in__O different__O countries__O during__O the__O same__O time:__O English__B-MISC =__O 582;__O Japanese__B-MISC =__O 315;__O Italian__B-MISC =__O 314;__O Chinese__B-MISC =__O 243;__O Dutch__B-MISC =__O 240;__O Bulgarian__B-MISC =__O 227;__O Spanish__B-MISC =__O 221;__O Finnish__B-MISC =__O 201;__O German__B-MISC =__O 201.__O
In__O many__O cases__O a__O single__O download__O is__O then__O used__O for__O several__O assessments.__O
The__O research__O has__O informed__O national__O guidelines__O through__O the__O involvement__O of__O Hyland__B-LOC and__O Jones__B-LOC on__O key__O committees.__O
Prof__B-PER Hyland__I-PER has__O acted__O as__O a__O member__O of__O the__O Outcome__B-ORG Assessment__I-ORG and__I-ORG Pulmonary__I-ORG Rehabilitation__I-ORG subcommittees__O of__O The__B-ORG National__I-ORG Strategy__I-ORG for__I-ORG COPD__I-ORG and__O the__O International__B-ORG Primary__I-ORG Care__I-ORG Respiratory__I-ORG Group__I-ORG where__O his__O research__O informed__O the__O production__O of__O guidelines__O on__O practice__O with__O a__O set__O of__O recommendations__O for__O patient__O management__O on__O the__O care__O of__O adults__O with__O difficult__O to__O manage__O asthma:__O http://www.theipcrg.org/download/attachments/1901269/Difficult+to+Manage+asthma+deskop+helper.pdf?version=1&amp;modificationDate=1335729880000.__O
)Dr__O Jones__B-PER has__O served__O on__O the__O Global__O emPOWER__B-MISC international__O education__O initiative__O for__O COPD__O editorial__O board__O (used__O in__O meetings__O involving__O 36,000__O primary__O clinicians__O in__O 28__O countries),__O COPD__O exchange__O editorial__O committee__O (producing__O a__O national__O COPD__B-ORG web__O based__O resource__O with__O over__O 7,500__O registered__O users),__O the__O British__B-ORG Thoracic__I-ORG Society__I-ORG review__O group__O producing__O Home__O Oxygen__B-MISC guidelines__O for__O Adults__B-ORG and__I-ORG Home__I-ORG Oxygen__I-ORG guidelines__O for__O Children,__B-LOC and__O served__O on__O the__O Main__B-MISC Implementation__I-MISC committee__O of__O National__B-ORG Strategy__I-ORG for__I-ORG COPD.__I-ORG
